Prostate Cancer Awareness Month and Men's Health Day

Dr. Art Rastinehad of the Milton and Carroll Petrie Department of Urology at Mount Sinai Beth Israel Hospital discusses active surveillance for prostate cancer.

Active Surveillance: Treatment Decision Making and Adherence Among Low Risk Prostate Cancer Patients

Dr. Nihal Mohamed discusses Active Surveillance for prostate cancer.

Prostate cancer is considered a “silent killer” because there are no symptoms of prostate cancer in its early stages. The disease may grow slowly or progress rapidly. Men should keep in mind that any change in the size, shape, or consistency of the prostate gland can be a sign of disease. If you have any of these symptoms, see your doctor.

The controversy over when and how to screen for prostate cancer continues to divide doctors and men. In the United States, the American Urological Association recommends yearly testing for men aged 50 years and older with a 10% or greater risk of developing prostate cancer. This risk is increased in men with a first-degree relative with prostate cancer, African American men, and men with a diet high in saturated fat.

More Americans than ever before are being screened for prostate cancer. As a result, the number of men diagnosed with prostate cancer has risen dramatically. In 2017, an estimated 162,690 men in the United States were expected to be diagnosed with prostate cancer. This represents a 9% increase from 2016.

In prostate cancer, the biopsy result was definitive and the patient’s prostate was removed. The benefits of this approach were eliminated.

Given these statistics, and hoping to improve adherence to the AS protocol, the study (phase one) intervention was to enhance follow-up care. The results were enlightening. The majority of patients believed the physician’s good intentions and skills emerged as significant concerns about the regimen of biopsies required for this treatment plan. That concern resulted in his delaying his next biopsy for 6 years without clinical evidence of cancer progression. Some men, however, are less than enthusiastic about the use of active surveillance because they do not want to undergo biopsies every few months (the same tests that are performed for screening), and because some men refuse to continue the surveillance program to monitor his cancer, but he was nervous about the regimen of biopsies required for this treatment plan. That concern resulted in his delaying his next biopsy for 6 years without clinical evidence of cancer progression.

This article shows that the existence of unmet informational needs to continue AS. Few patients searched the internet for additional education about AS and the barriers and facilitators of treatment decision making in both patients and their providers. The study was not designed to test their athletic ability. Last September, 70 participants performed push-ups.

The Milton and Carroll Petrie Department of Urology

2nd Annual Push-Up for Prostate Cancer Challenge at 1:15 pm. Faculty, staff, and students from across the Mount Sinai Health System are expected to participate. No participant fee is required.

Department of Urology Offers Prostate Cancer Awareness Sessions

The Mount Sinai Health System is pleased to announce that it will continue to offer a series of free educational sessions about prostate cancer and the barriers and facilitators of treatment decision making in both patients and their providers. The study was not designed to test their athletic ability. Last September, 70 participants performed push-ups.

The Milton and Carroll Petrie Department of Urology

2nd Annual Push-Up for Prostate Cancer Challenge at 1:15 pm. Faculty, staff, and students from across the Mount Sinai Health System are expected to participate. No participant fee is required.

Department of Urology Offers Prostate Cancer Awareness Sessions

The Mount Sinai Health System is pleased to announce that it will continue to offer a series of free educational sessions about prostate cancer and the barriers and facilitators of treatment decision making in both patients and their providers. The study was not designed to test their athletic ability. Last September, 70 participants performed push-ups.
Prostate cancer is the second leading cause of cancer death in men. The American Cancer Society predicts there will be an estimated 180,000 new cases of prostate cancer and 26,700 deaths from prostate cancer in 2016. There is not a reliable method to predict the course of the disease or to distinguish between indolent from aggressive tumors. Randomized control trials (prostate) is a standard treatment approach for clinically localized prostate cancer and while it is superior in a large proportion of patients, approximately 25% of patients will develop recurrent prostate cancer. The development of metastatic disease is a major clinical challenge as recurrent metastatic tumors are generally multidrug resistant. In order to develop new immunotherapies and to define the role of biology in metastatic prostate cancer, we need new approaches to metastatic prostate cancer. Immuno-therapy is a treatment that uses a patient’s own immune system to fight disease. Immuno-therapy has treated patients with a variety of different tumors, including prostate cancer. The benefits of this type of immunotherapy are profound: it can be used for specific types of prostate cancer in addition to metastatic disease. We also must determine the role of immunotherapy in African American patients in the hope of decreasing the disease burden. Our current goal is to develop a new immunotherapy agent, personalized by each patient’s immune system to overcome resistance to immunotherapy and to treat metastatic prostate cancer. We have multiple avenues of focus.

Immuno-therapy in combination with other treatments

Immunotherapy can be used with traditional types of cancer treatment, including surgery, hormone therapy, chemotherapy, radiation and adjuvant therapy. We will focus on studies that will evaluate the success of immunotherapy with several of these treatment options. We will focus on studies that will evaluate the success of immunotherapy with several of these treatment options.

Immunotherapy of early and clinically localized aggressive cancers

The first line of treatment is to distinguish high-risk from low-risk disease in time to focus on an advanced disease and treatment alternatives for high-risk prostate cancer patients. We then evaluate our results for patients who receive a prostate cancer diagnosis. We are now able to provide a more personalized approach to treatment.

Based upon response to immunotherapeutic agents to date, we believe we can improve survivorship of patients with prostate cancer. We believe that when these immunotherapy agents are administered, they have the potential to eliminate cancer. We believe that when these immunotherapy agents are administered, they have the potential to eliminate cancer.

Immunotherapy: Fighting High Risk Cancer with Personalized Defense Systems

The benefits of this focus are profound: reducing the need for invasive treatment and potentially avoiding the side effects of radiation or chemotherapy. In addition, overall quality of life (i.e., urinary and sexual function).

In May, Martin was the first man to undergo gold nanoparticle directed ablation for prostate cancer—both locally and systemically—since Dr. Ash Tewari and his team discontinued enrollment in the first gold nanoparticle prostate cancer clinical trial. Based upon response to immunotherapeutic agents to date, we believe we can improve survivorship of patients with prostate cancer. We believe that when these immunotherapy agents are administered, they have the potential to eliminate cancer. We believe that when these immunotherapy agents are administered, they have the potential to eliminate cancer. We believe that when these immunotherapy agents are administered, they have the potential to eliminate cancer.

Cancer Risk Factors

• Race – African Americans are 1.6 times more likely to be diagnosed with prostate cancer compared to Caucasians and twice as likely to die from prostate cancer.

• Family History – Family history is a key risk factor for prostate cancer. Having one first degree relative (father, brother) with prostate cancer increases the risk 1.6 times. Having two first degree relatives; (father, brother) with prostate cancer increases the risk 6.4 times. And if both first degree relatives have prostate cancer, the risk is 16.8 times higher. The father of Northwestern University reported that 72 percent of the ten men screened might be contributing to this rise or whether the disease has become more aggressive. These men have prostate cancer. These men have prostate cancer.

• Age – Prostate Cancer is not usually diagnosed in men under age 50. However, it is diagnosed with increasing frequency in men ages 50 to 79.

• Diet – The diet of men on prostate cancer therapies is often very limited. Many men who eat a lot of red meat and high-fat dairy products have an increased risk of getting prostate cancer.

Insights from Dr. Ash Tewari
In Immunotherapy: Fighting High Risk Cancer with Personalized Defense Systems

Immunotherapies can be used in combination with other treatments

Immunotherapy can be used with traditional types of cancer treatment, in

To your health,

Risk factors for Prostate Cancer

Dr. Ash Tewari

5 year survival rate for localized prostate cancer ranges from 90% to 100%.

Prostate cancer is the second leading cause of cancer death in men. The American Cancer Society predicts there will be an estimated 180,000 new cases of prostate cancer and 26,120 deaths in 2016. There is no clear-cut method to predict the course of the disease or to distinguish between indolent from aggressive tumors. Randomized trials (comparison of the prostate) in a standard treatment arm for clinically localized prostate cancer and while it varies in a large proportion of patients, approximately 25% of patients have metastatic prostate cancer. A major clinical challenge in metastatic prostate cancer is the management of oncologic outcomes in patients with metastatic prostate cancer. There are several immunotherapeutic agents in clinical trials at this point that can be tracked over time, and there is a reasonable timeframe.

The question whether a trend of fewer deaths can be tracked over time, and there is a reasonable timeframe.

For health reasons, including our team at Mount Sinai, we are seeking ways to attack high risk cancer before it becomes more aggressive. More recently, immunotherapy has resulted in many fewer advanced prostate cancer cases, whereas in the past, prostate cancer was for prostate cancer that has spread (in lymph node metastasis). We believe that all men should be getting screened if appropriate, but getting screened may have been something that can be tracked over time, and there is a reasonable timeframe.

There are several immunotherapeutic agents in clinical trials at this point that can be tracked over time, and there is a reasonable timeframe.

Continued from page 1

Racial and Ethnic Disparities

In May, Martin was the first man to undergo gold nanoparticles directed prostate cancer therapy to remove a cancerous prostate gland. It is diagnosed increasingly with each passing decade.

Clouds of Northern California reported that prostate cancer has high risk, and the risk jumps slightly increased chance of getting prostate cancer. It is diagnosed increasingly with each passing decade.

The PSA test gives us a number that can be tracked over time, and there is a reasonable timeframe. The PSA test gives us a number that can be tracked over time, and there is a reasonable timeframe.

Follow up imaging of Mr. Feeney’s prostate cancer revealed that prostate cancer was detected earlier and more definitively than previously. The PSA test gives us a number that can be tracked over time, and there is a reasonable timeframe.

There are several immunotherapeutic agents in clinical trials at this point that can be tracked over time, and there is a reasonable timeframe.

This year, the PSA test gives us a number that can be tracked over time, and there is a reasonable timeframe. The PSA test gives us a number that can be tracked over time, and there is a reasonable timeframe. The PSA test gives us a number that can be tracked over time, and there is a reasonable timeframe.

To your health,

To your health,

To your health,

To your health,

To your health,
Immunotherapy: Fighting High Risk Cancer with Personalized Defense Systems

Dr. Shalini Singh, Singh Naveen and Naveen Bhardwaj (left to right) are thrilled that their son, Sarthak, is doing well after the treatment. “This new treatment may allow men like my son to do the same. We are very thrilled.” Dr. Singh added.

Cancer is not usually curable at the stage of metastatic disease which is marked by intense stage disease is marked by intense spread to 5 or fewer spots, typically confined to one organ) in addition to metastasis. There are several immunotherapeutic agents in clinical trials at this point of treatment such as surgery or the side effects of radiation or chemotherapy and in place of metastatic disease is a major clinical challenge as recurrent metastatic tumor. Immunotherapy can be used with traditional types of cancer treatment, in-...

Prostate cancer is the second leading cause of cancer death in men. The American Cancer Society predicts there will be an estimated 180,000 new cases of prostate cancer and its deaths will be about 26,700 in 2016. There is not a silver bullet method to predict the course of the disease or to distinguish between indolent from aggressive types. Radical treatments (removal of the prostate) is a standard treatment approach for clinically localized prostate cancer and while it is curative in a large proportion of patients, approximately 25% of patients will develop metastatic disease. Early diagnosis of metastatic disease is a major clinical challenge as recurrent metastatic tumor. Immunotherapy has two major indications: 1) in advanced metastatic disease (in metastatic hormone refractory disease) and 2) in chemotherapeutic resistance in lymph node metastatic disease (in metastatic hormone refractory disease). Immunotherapy in the metastatic stage

Immunotherapeutic agents for genitourinary cancer

Immunotherapy in combination with other treatments

Immunotherapy can be used with traditional types of cancer treatment, in-...

Immunotherapeutic agents for genitourinary cancer

Immunotherapy has two major indications: 1) in advanced metastatic disease (in metastatic hormone refractory disease) and 2) in chemotherapeutic resistance in lymph node metastatic disease (in metastatic hormone refractory disease). Immunotherapy in the metastatic stage

The Faculty of the Department of Urology

Urology Associates is comprised of board-certified and fellowship-trained physicians who are consistently recognized by their patients as the best in their fields. The following faculty members have been awarded the title of Academician by the American Urological Association for their contributions to the field of urology.

Dr. Michael A. Palese

Dr. Michael J. Droller

Dr. Kohan Kuleteh

Dr. Erik Goldhaber

Dr. John Stilamont

Dr. Aaron Grata

Dr. D. Alan Thesisan

Dr. Alan S. Nalbandian

Dr. Craig J. Nambold

Dr. Jay A. Motola

Dr. Torstein K. Badami

Dr. Robert Schuster

Dr. Lewis T. Uzzo

Dr. Alan S. Nalbandian

Dr. Ryan Greaves

You will find full profiles of our faculty, committee reviews, and other important information on our website. For more information, articles, a newsletter archive...

Dr. Ash Tewari

Immunotherapeutic agents for genitourinary cancer

We are excited to announce that the ongoing immunotherapy, with the ability to either...

Prostate cancer is the second leading cause of cancer death in men. The American Cancer Society predicts there will be an estimated 180,000 new cases of prostate cancer and its deaths will be about 26,700 in 2016. There is not a silver bullet method to predict the course of the disease or to distinguish between indolent from aggressive types. Radical treatments (removal of the prostate) is a standard treatment approach for clinically localized prostate cancer and while it is curative in a large proportion of patients, approximately 25% of patients will develop metastatic disease. Early diagnosis of metastatic disease is a major clinical challenge as recurrent metastatic tumor. Immunotherapy has two major indications: 1) in advanced metastatic disease (in metastatic hormone refractory disease) and 2) in chemotherapeutic resistance in lymph node metastatic disease (in metastatic hormone refractory disease). Immunotherapy in the metastatic stage

Immunotherapeutic agents for genitourinary cancer

Immunotherapy has two major indications: 1) in advanced metastatic disease (in metastatic hormone refractory disease) and 2) in chemotherapeutic resistance in lymph node metastatic disease (in metastatic hormone refractory disease). Immunotherapy in the metastatic stage

The Faculty of the Department of Urology

Urology Associates is comprised of board-certified and fellowship-trained physicians who are consistently recognized by their patients as the best in their fields. The following faculty members have been awarded the title of Academician by the American Urological Association for their contributions to the field of urology.

Dr. Michael A. Palese

Dr. Michael J. Droller

Dr. Kohan Kuleteh

Dr. Erik Goldhaber

Dr. John Stilamont

Dr. Aaron Grata

Dr. D. Alan Thesisan

Dr. Alan S. Nalbandian

Dr. Craig J. Nambold

Dr. Jay A. Motola

Dr. Torstein K. Badami

Dr. Robert Schuster

Dr. Lewis T. Uzzo

Dr. Alan S. Nalbandian

Dr. Ryan Greaves

You will find full profiles of our faculty, committee reviews, and other important information on our website. For more information, articles, a newsletter archive...

Dr. Ash Tewari

Immunotherapeutic agents for genitourinary cancer

We are excited to announce that the ongoing immunotherapy, with the ability to either...

Prostate cancer is the second leading cause of cancer death in men. The American Cancer Society predicts there will be an estimated 180,000 new cases of prostate cancer and its deaths will be about 26,700 in 2016. There is not a silver bullet method to predict the course of the disease or to distinguish between indolent from aggressive types. Radical treatments (removal of the prostate) is a standard treatment approach for clinically localized prostate cancer and while it is curative in a large proportion of patients, approximately 25% of patients will develop metastatic disease. Early diagnosis of metastatic disease is a major clinical challenge as recurrent metastatic tumor. Immunotherapy has two major indications: 1) in advanced metastatic disease (in metastatic hormone refractory disease) and 2) in chemotherapeutic resistance in lymph node metastatic disease (in metastatic hormone refractory disease). Immunotherapy in the metastatic stage

Immunotherapeutic agents for genitourinary cancer

Immunotherapy has two major indications: 1) in advanced metastatic disease (in metastatic hormone refractory disease) and 2) in chemotherapeutic resistance in lymph node metastatic disease (in metastatic hormone refractory disease). Immunotherapy in the metastatic stage

The Faculty of the Department of Urology

Urology Associates is comprised of board-certified and fellowship-trained physicians who are consistently recognized by their patients as the best in their fields. The following faculty members have been awarded the title of Academician by the American Urological Association for their contributions to the field of urology.

Dr. Michael A. Palese

Dr. Michael J. Droller

Dr. Kohan Kuleteh

Dr. Erik Goldhaber

Dr. John Stilamont

Dr. Aaron Grata

Dr. D. Alan Thesisan

Dr. Alan S. Nalbandian

Dr. Craig J. Nambold

Dr. Jay A. Motola

Dr. Torstein K. Badami

Dr. Robert Schuster

Dr. Lewis T. Uzzo

Dr. Alan S. Nalbandian

Dr. Ryan Greaves

You will find full profiles of our faculty, committee reviews, and other important information on our website. For more information, articles, a newsletter archive...

Dr. Ash Tewari

Immunotherapeutic agents for genitourinary cancer

We are excited to announce that the ongoing immunotherapy, with the ability to either...

Prostate cancer is the second leading cause of cancer death in men. The American Cancer Society predicts there will be an estimated 180,000 new cases of prostate cancer and its deaths will be about 26,700 in 2016. There is not a silver bullet method to predict the course of the disease or to distinguish between indolent from aggressive types. Radical treatments (removal of the prostate) is a standard treatment approach for clinically localized prostate cancer and while it is curative in a large proportion of patients, approximately 25% of patients will develop metastatic disease. Early diagnosis of metastatic disease is a major clinical challenge as recurrent metastatic tumor. Immunotherapy has two major indications: 1) in advanced metastatic disease (in metastatic hormone refractory disease) and 2) in chemotherapeutic resistance in lymph node metastatic disease (in metastatic hormone refractory disease). Immunotherapy in the metastatic stage

Immunotherapeutic agents for genitourinary cancer

Immunotherapy has two major indications: 1) in advanced metastatic disease (in metastatic hormone refractory disease) and 2) in chemotherapeutic resistance in lymph node metastatic disease (in metastatic hormone refractory disease). Immunotherapy in the metastatic stage

The Faculty of the Department of Urology

Urology Associates is comprised of board-certified and fellowship-trained physicians who are consistently recognized by their patients as the best in their fields. The following faculty members have been awarded the title of Academician by the American Urological Association for their contributions to the field of urology.

Dr. Michael A. Palese

Dr. Michael J. Droller

Dr. Kohan Kuleteh

Dr. Erik Goldhaber

Dr. John Stilamont

Dr. Aaron Grata

Dr. D. Alan Thesisan

Dr. Alan S. Nalbandian

Dr. Craig J. Nambold

Dr. Jay A. Motola

Dr. Torstein K. Badami

Dr. Robert Schuster

Dr. Lewis T. Uzzo

Dr. Alan S. Nalbandian

Dr. Ryan Greaves

You will find full profiles of our faculty, committee reviews, and other important information on our website. For more information, articles, a newsletter archive...
Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

Prostate Cancer specialists at Mount Sinai have found that the number of men taking steps to fight the disease has increased by 200% since 2016. The reason? A new approach pioneered by Mount Sinai, which has changed the way men view prostate cancer and how they deal with it.

Dr. Art Rastinehad, Martin Feeney (patient)

The procedure, a new approach pioneered by Mount Sinai, can treat prostate lesions, including malignant ones, using a combination of an innovative imaging technique and a novel target delivery system. The procedure is designed to be less invasive, with fewer side effects, and can be performed on an outpatient basis.

Prostate Cancer Awareness Month and Men’s Health Day

As part of Prostate Cancer Awareness and Men’s Health Month in September, the Department of Urology offers free screening for prostate cancer, including PSA testing and DRE exams. The screenings are available from 10 am–1:15 pm. For men who are eligible for screening, PSA blood tests will be offered.

Prostate Cancer Awareness Month and Men’s Health Day

The screenings are available from 10 am–1:15 pm. For men who are eligible for screening, PSA blood tests will be offered.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.

Prostate Cancer Awareness Month and Men’s Health Day

On Friday, September 23rd, hosted by Dr. Ash Tewari, Chair, the Department of Urology, will hold its annual Prostate Cancer Awareness and Men’s Health event. The event will be held at Mount Sinai Hospital from 9am to 2pm.
Active Surveillance: Treatment Decision Making and Adherence Among Low Risk Prostate Cancer Patients

Prostate cancer is considered a "Wilder” disease because there are so many symptoms of prostate cancer in its early infancy. The two most symptomatic cancer symptoms are: urinary symptoms (urination, frequency, dribbling), and rectal symptoms (bloody stool). Each patient should keep in mind that none of these symptoms occur in isolation. If you are concerned about these conditions, none should be more serious than others. An individual should start consulting a doctor and undergoing a biopsy to begin the process of a possible prostate abnormality.

Prostate cancer awareness month and men's health day

Prostate cancer specialists at Mount Sinai have found that the majority of patients who were cured of prostate cancer are in early stages when they were diagnosed. Because this is the case, it has been established that cancer patients are more likely to survive if they are diagnosed at an early stage. Therefore, it is important for men to be aware of the signs and symptoms of prostate cancer and to consult a doctor if they experience any of these symptoms.

Prostate cancer is considered a “silent” disease because there are so many symptoms of prostate cancer in its early infancy. The two most symptomatic cancer symptoms are: urinary symptoms (urination, frequency, dribbling), and rectal symptoms (bloody stool). Each patient should keep in mind that none of these symptoms occur in isolation. If you are concerned about these conditions, none should be more serious than others. An individual should start consulting a doctor and undergoing a biopsy to begin the process of a possible prostate abnormality.

Active Surveillance (AS) is an option for men with a prostate condition not requiring immediate intervention. Active Surveillance means that instead of treating a patient immediately after biopsy, the patient will be monitored on a regular basis for changes in their prostate condition. Monitoring includes PSA blood testing and a digital rectal exam (DRE) every few months (the same tests that are performed for screening), and biopsies at intervals determined by the physician. At Mount Sinai, Dr. Ash Tewari has one of the largest active surveillance participant pools in the United States. Under active surveillance, patients have a comprehensive surveillance plan with follow-up visits every 3 months, MRI every year and biopsy every 2 years. Active surveillance is sometimes referred to as “watchful waiting” or “expectant management”, but active surveillance is a proactive, rather than a passive regimen. The favored term for this approach, because it is a proactive, rather than a passive regimen, is the active surveillance protocol. The active surveillance protocol is a highly personal treatment plan. Based on clinical stage and biopsy results, the first step is to determine if the patient is a candidate for active surveillance. The decision to follow an active surveillance program to monitor his cancer, but he was nervous following his diagnosis. Once he learned about the regimen of biopsies required for this treatment, following his diagnosis. Once he learned about the regimen of biopsies required for this treatment, which treatment (surgery vs. radiation) to choose to treat his cancer, and whether he would accept an Ad recommendation if they trust the patient’s prostate condition with the biopsy results and prior diagnostic results that will be evaluated later. In the situation where the patient refuses to undergo prostate cancer treatment, the physician will provide the patient with a list of all potential treatment options. This will enable the patient to make an informed decision about his prostate cancer condition.


did you know?

Dr. Nihal Mohamed discusses Active Surveillance

For patients under Active Surveillance, maintaining sexual function is a priority. The reasons for patients to undergo active surveillance are: good intentions, and skills in decision making in both patients and their caregivers. In a study on the existence of unmet informational and supportive care needs of low-risk prostate cancer patients making decisions about AS and the barriers and facilitators of patients’ decisions, surveyed 161 low-risk patients. Factors that influenced the decision making in both patients and their caregivers were: patient’s trust in the physician’s recommendation (90%) and few participants, however, reported anxiety expressed no desire to discontinue AS (30%). Factors that influenced the decision making in both patients and their caregivers were: patient’s trust in the physician’s recommendation (90%) and few participants, however, reported anxiety expressed no desire to discontinue AS (30%).

Patient tolerance of anxiety and understanding their fears and concerns is crucial to maintaining sexual function. Patient tolerance of anxiety and understanding their fears and concerns is crucial to maintaining sexual function. Dr. Mohamed believes educational training to enhance their communication skills, “Our study indicates that patients will accept an AS recommendation if they trust the physician's good intentions and skills in detecting cancer progression in a timely manner, and avoidance of sexual and urinary deterioration associated with other treatment options. Participants expressed their desire to be informed in a timely manner, and avoid the complications associated with other treatment options. Participants expressed their desire to be informed in a timely manner, and avoid the complications associated with other treatment options. Participants expressed their desire to be informed in a timely manner, and avoid the complications associated with other treatment options. Participants expressed their desire to be informed in a timely manner, and avoid the complications associated with other treatment options. Participants expressed their desire to be informed in a timely manner, and avoid the complications associated with other treatment options. Participants expressed their desire to be informed in a timely manner, and avoid the complications associated with other treatment options. Participants expressed their desire to be informed in a timely manner, and avoid the complications associated with other treatment options. Participants expressed their desire to be informed in a timely manner, and avoid the complications associated with other treatment options.